1 Background {#Sec1}
============

Fanconi anemia (FA) is a rare, recessive, genetically heterogeneous, chromosomal instability disorder, characterized by developmental abnormalities, retarded growth, bone marrow failure, and a high risk for the development of cancer (Auerbach et al. [@CR3]; Alter [@CR1]; Rosenberg et al. [@CR57]; Kutler et al. [@CR40]). Fanconi anemia patient-derived cells are extremely sensitive to bifunctional alkylating or DNA interstrand cross-linking agents, such as mitomycin C and cisplatin (Ishida and Buchwald [@CR32]; Wang [@CR79]).

Currently, sixteen FA genes have been identified, each corresponding to a distinct 'complementation group': FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, -P, and -Q (Strathdee et al. [@CR69]; Pronk et al. [@CR56]; Apostolou et al. [@CR2]; Lo Ten Foe et al. [@CR46]; de Winter et al. [@CR13], [@CR14], [@CR15]; Waisfisz et al. [@CR78]; Timmers et al. [@CR73]; Howlett et al. [@CR31]; Meetei et al. [@CR49], [@CR50], [@CR51]; Levitus et al. [@CR41]; Levran et al. [@CR42]; Dorsman et al. [@CR19]; Xia et al. [@CR84]; Smogorzewska et al. [@CR64]; Sims et al. [@CR63]; Vaz et al. [@CR76]; Kim et al. [@CR36]; Stoepker et al. [@CR68]; Bogliolo et al. [@CR6]); the most common groups being FA-A, -C, and -G, together accounting for 85% of all FA patients (Levran et al. [@CR43]; de Winter and Joenje [@CR12]).

To maintain genome integrity, the FA proteins function together in the so-called FA/BRCA-pathway to repair DNA damage, such as double strands breaks (DSBs). The FA/BRCA-pathway is divided into an upstream and a downstream branch in relation to the monoubiquitination of FANCD2 and FANCI, which is considered a central activating reaction. This reaction is catalyzed by the so-called core complex, which is thought to be assembled via subcomplexes. These complexes are FANC-A and -G; FANC-B and -L; FANC-E, -C, and -F. Together with FANCM these proteins constitute the core complex (Medhurst et al. [@CR48]). The activation of FANCD2 and FANCI coordinates the activities of FA proteins that act downstream in the pathway leading to DNA repair: FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4, FANCQ/ERCC4/XPF and XRCC2. Homozygous germ line mutations in *BRCA1* can result in a Fanconi anemia-like phenotype (Domchek et al. [@CR18]; D'Andrea [@CR11]), *BRCA1* may thus be considered an FA-like gene whose action may thus be closely connected to the FA pathway.

In addition to their involvement in the canonical FA/BRCA-pathway acting either in the upstream, central, or downstream part, additional protein complexes of FA proteins have been described that may serve distinct or related functions, such as FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (Wilson et al. [@CR81]), and FANCA-BRCA1 (Folias et al. [@CR21]). Moreover, some FA proteins appear to function in additional, seemingly unrelated, processes such as oxidative metabolism, cell cycle progression, apoptosis, and transcriptional regulation, which may be relevant for some of the pathological features of FA (Kaddar and Carreau [@CR33]).

Biallelic mutations in the genes underlying the FA/BRCA-pathway cause predisposition to malignancies in FA patients. On the other hand, there is evidence that a proportion of cancers arising in the (non-FA) general populations ('sporadic cancers') may possess a disrupted FA/BRCA pathway (Stecklein and Jensen [@CR66]). The status of this pathway appears to be relevant for cancer treatment response. Repression has been associated with a favorable response against cross-linking drugs (Chen et al. [@CR8]; Stecklein and Jensen [@CR66]), whereas hyperactivation might be responsible for resistance to such drugs.

Upregulation of several FA genes, especially during S phase, has been linked to the RB1/E2F pathway (Tategu et al. [@CR72]; Hoskins et al. [@CR29]; Kim and D'Andrea [@CR35]), which is known to control cell cycle progression (Nevins [@CR54]; Chen et al. [@CR9]; Knudsen and Wang [@CR38]). This pathway plays an important role in transcriptional regulation during the cell cycle. Proteins of the RB1 family, pRb, p107 and p130 work together with the sequence-specific DNA-binding factors of the E2F family which consists of the activators E2F1-E2F3 and repressors E2F4-E2F8 (Chen et al. [@CR9]; Di Fiore et al. [@CR17]). During growth arrest, E2F activity can be repressed by the RB1 protein family via protein-protein interactions, while during progression to the cell cycle from G1 to S phase phosphorylation of the RB1 family members results into E2F activation (Henley and Dick [@CR25]). Since disruption of the RB1/E2F pathway and upregulation of E2F target genes is frequently observed in human cancers (Nevins [@CR54]; Chen et al. [@CR9]; Knudsen and Wang [@CR38]) upregulation of (a subset) of FA genes may be a common feature for tumors with a disrupted RB1 pathway.

In this study we monitored expression of 14 FA genes during the cell cycle and in cancers with a disrupted RB1/E2F pathway, in an attempt to identify gene expression patterns that characterize two important interconnected pathways, i.e. the FA and RB1/E2F pathways.

2 Results {#Sec2}
=========

2.1 Upregulation of the FA mRNA level upon progression through the cell cycle in two cell models {#Sec3}
------------------------------------------------------------------------------------------------

To study the expression of FA genes during the cell cycle, we used the established human cell-cycle model T98G derived from glioblastoma cells (Stein [@CR67]). T98G cells can be efficiently arrested via serum deprivation, while after serum stimulation a synchronized progression through the cell cycle can be observed. T98G cells express abundant levels of E2F activity and possess a functional RB pathway (Takahashi et al. [@CR71]). Fluorescent Activated Cell Sorting (FACS) analysis and *CCNE2* expression confirmed the proper synchronization of the cells (Figure [1](#Fig1){ref-type="fig"}a - left and right panel).Figure 1**Differential cell cycle regulation of FA genes in human T98G cells. (a-left panel)** FACS analysis of synchronized cells, the 0, 8, 12, 16, 18, 20, 22, 24, 28, and 32 hr time points are shown; S phase is most pronounced between 18--22 hrs. Data of FACS represents one representative synchronization **(a-right panel)** Control experiment: The mRNA levels of *CCNE2* during the cell cycle are shown. Quantitative RT-PCR was performed on total RNA samples from different time points and mean fold changes (MFC) were calculated relative to time point zero. Data represents the average mean fold change of 2--3 independent synchronization each in duplicate qPCR measurement (except for time points: 28 and 32) **(b-g)** Relative gene expression during the cell cycle for genes encoding in the FA/BRCA-pathway.

The mRNA expression levels of the following endogenous FA genes (*FANC-A, -B, -C, -E, -F, -G, -L, -M*, *-D2*, *-I*, *-D1*, *-N*, *-J*, and *BRCA1*) were analyzed with RT-qPCR. Changes in mRNA levels were subsequently calculated relative to time point zero. Several of the FA genes turned out to be prominently induced during the cell cycle progression (Figure [1](#Fig1){ref-type="fig"}b-g), e.g. *FANCA* (Figure [1](#Fig1){ref-type="fig"}b) while other FA genes, like *FANCL* (Figure [1](#Fig1){ref-type="fig"}c) and *FANCF* (Figure [1](#Fig1){ref-type="fig"}d) showed a relatively constitutive expression pattern during the cell cycle.

We also compared the expression of endogenous FA genes during the cell cycle in human diploid fibroblasts (EVA-F) via serum deprivation (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). FACS analysis (Additional file [1](#MOESM1){ref-type="media"}: Figure S1a - left panel) and expression analysis of *CCNE2* confirmed the proper synchronization of the cells (Additional file [1](#MOESM1){ref-type="media"}: Figure S1a - right panel). In this instance, also a subset of the FA genes turned out to be prominently upregulated during the cell cycle relative to time point zero, again *FANCA* (Additional file [1](#MOESM1){ref-type="media"}: Figure S1b), but also *FANCD2* (Additional file [1](#MOESM1){ref-type="media"}: Figure S1f) and *BRIP1* (Additional file [1](#MOESM1){ref-type="media"}: Figure S1g); while other FA genes, like again *FANCL* (Additional file [1](#MOESM1){ref-type="media"}: Figure S1c) and *FANCF* (Additional file [1](#MOESM1){ref-type="media"}: Figure S1d), were less affected during the cell cycle progression.

2.2 Upregulation of FA gene expression in cancers associated with disrupted RB1/E2F pathway {#Sec4}
-------------------------------------------------------------------------------------------

To study the upregulation of the FA/BRCA-pathway in cancers with a disrupted RB1/E2F pathway, two different primary human tumors, retinoblastoma (Rb) and basal breast cancer were studied. The vast majority of retinoblastomas harbors mutations in *RB1* (Dunn et al. [@CR20]), while it has been recently recognized that functional loss of *RB1* is a common event in basal like breast tumors (Herschkowitz et al. [@CR27]). To discriminate between upregulation caused by altered regulation of expression or by DNA copy number alteration (CNA), we determined the correlation between CNA and mRNA expression of FA/BRCA genes (Henrichsen et al. [@CR26]; Dear [@CR16]; Kuiper et al. [@CR39]).

### 2.2.1 Upregulation of FA genes in *RB1-*mutated retinoblastoma versus fetal retina {#Sec5}

We analyzed the gene expression in a cohort of primary retinoblastoma tumors and compared that to healthy fetal retina samples. We found a significant upregulation in retinoblastoma tumors (most significant Fold Changes \[FCs\] indicated, for all probes and corresponding FCs see Table [1](#Tab1){ref-type="table"}), for the core complex members: *FANCA* (FC = 3.54, P = 2.32E-06), *FANCC* (FC = 1.48, P = 3.25E-03), *FANCE* (FC = 1.93, P = 2.07E-02), *FANCG* (FC = 4.00, P = 1.52E-07), *FANCL* (FC = 2.65, P = 4.95E-09), *FANCM* (FC = 1.51, P = 2.08E-02); central players: *FANCD2* (FC = 1.95, P = 4.68E-03) and *FANCI* (FC = 2.69, P = 1.55E-03); and for the downstream branch: *FANCD1/BRCA2* (FC = 2.90, P = 4.65E-04), *FANCN/PALB2* (FC = 2.18, P = 8.70E-09), and *BRCA1* (FC = 2.05, P = 2.13E-04) compared to healthy fetal retina. For the core complex member *FANCF* we found a significant downregulation (FC = -1.81, P = 1.30E-04). For the core complex member *FANCB* and downstream branch member *FANCJ/BRIP1* no significant differences were detected compared to healthy fetal retina. The upregulation of *FANCE* was driven by CNA since a linear statistical significant correlation was found between CNA and mRNA expression (FDR P-value cut-off 5.00E-02; Table [2](#Tab2){ref-type="table"}).Table 1**Gene expression in Retinoblastoma tumors versus fetal retina**PartGene symbolProbe IDFold changeP-value^\*^Core complexFANCA203805_PM_s\_at2.206.06E-03FANCA203806_PM_s\_at3.542.32E-06FANCA236976_PM_at4.002.68E-06FANCC242654_PM_at1.483.25E-03FANCC205189_PM_s\_at1.492.77E-02FANCC1559513_PM_a\_at1.526.28E-03FANCE220255_PM_at1.932.07E-02FANCF218689_PM_at-1.811.30E-04FANCF222713_PM_s\_at-1.372.65E-02FANCG203564_PM_at4.001.52E-07FANCL218397_PM_at2.654.95E-09FANCM234733_PM_s\_at1.512.08E-02FANCM242711_PM_x\_at1.562.27E-02Central playersFANCD2242560_PM_at1.954.68E-03FANCI223785_PM_at1.692.47E-02FANCI213008_PM_at2.553.08E-03FANCI213007_PM_at2.691.55E-03Downstrem branchBRCA2214727_PM_at2.315.87E-03BRCA2208368_PM_s\_at2.904.65E-04PALB2219530_PM_at2.188.70E-09BRCA1204531_PM_s\_at2.052.13E-04Acitvating E2FsE2F1204947_PM_at1.615.47E-03E2F12028_PM_s\_at1.862.56E-03E2F2228361_PM_at2.842.31E-04E2F3203692_PM_s\_at3.501.94E-08E2F3203693_PM_s\_at3.722.18E-10ControlCCNE2211814_PM_s\_at7.773.13E-10CCNE2205034_PM_at8.881.22E-11^\*^Cutoff P-value \< 0.05.Table 2**Significant correlation copy number variation and mRNA in retinoblastoma**Gene symbolProbe IDLinear correlationP-valueFDR P-value^\*^FANCE220255_PM_at2.252.03E-073.24E-05E2F3203692_PM_s\_at1.651.99E-085.78E-06E2F3203693_PM_s\_at1.501.81E-085.34E-06^\*^Cutoff FDR P-value \< 0.05.

Interestingly, in *MYCN*-amplified (without *RB1* mutations) retinoblastoma (Rushlow et al. [@CR58]) compared to *RB1-*mutated retinoblastomas, we found a significant downregulation of the core complex members: *FANCA* (FC = -3.99, P = 3.69E-03), *FANCC* (FC = -1.91, P = 1.46E-02), *FANCL* (FC = -2.56, P = 2.72E-06), *FANCM* (FC = -2.07, P = 2.16E-02); central player: *FANCI* (FC = -3.74, P = 1.56E-02); and downstream branch member *BRCA1* (FC = -2.36, P = 8.85E-03; Additional file [2](#MOESM2){ref-type="media"}: Table S1) compared to classic retinoblastoma (with *RB1* mutations). This provided additional evidence that the disrupted RB1/E2F-pathway in the *RB1-*mutated retinoblastoma tumors may play a role in upregulation of the FA/BRCA-pathway members.

### 2.2.2 Upregulation of FA genes in basal versus not-basal breast tumors {#Sec6}

We compared 41 basal breast tumors (27 *BRCA1*-mutated) and 79 not-basal breast tumors (8 *BRCA1* mutated) for FA gene expression (Table [3](#Tab3){ref-type="table"}). A significant upregulation in basal breast tumors compared to not-basal tumors was found for the core complex members: *FANCA* (FC = 3.40, P = 1.93E-13), *FANCB* (FC = 4.73, P = 5.18E-12), *FANCC* (FC = 1.38, P = 3.38E-04), *FANCE* (FC = 1.62, P = 2.80E-08), *FANCG* (FC = 1.39, P = 1.52E-06), *FANCL* (FC = 1.52, P = 3.79E-06); central players: *FANCD2* (FC = 1.66, P = 4.57E-06) and *FANCI* (FC = 1.98, P = 1.46E-06); and for the downstream branch: *FANCD1/BRCA2* (FC = 1.96, P = 3.45E-09), and *FANCJ/BRIP1* (FC = 1.96, P = 5.75E-05). A significant downregulation was found for the core complex members *FANCF* (FC = -1.29, P = 2.60E-03), and *FANCM* (FC = -1.28, P = 1.26E-02). No significant differences were detected for the downstream branch member: *FANCN/PALB2*. The expression status of *BRCA1* is influenced by mutation status therefore we consider it unknown.Table 3**Gene expression in basal breast tumors versus not-basal**PartGene symbolProbe IDFold changeP-value^\*^Core complexFANCA215530_at1.516.41E-03FANCA236976_at2.077.57E-04FANCA203806_s\_at3.062.74E-12FANCA203805_s\_at3.401.93E-13FANCB243597_at1.955.10E-05FANCB1553244_at2.381.26E-05FANCB1557217_a\_at3.063.02E-07FANCB1557218_s\_at4.735.18E-12FANCC205189_s\_at1.383.38E-04FANCE220255_at1.622.80E-08FANCF218689_at-1.292.60E-03FANCG203564_at1.391.52E-06FANCL218397_at1.523.79E-06FANCM242711_x\_at-1.281.26E-02Central playersFANCD2242560_at1.664.57E-06FANCD2223545_at1.742.22E-05FANCI223785_at1.601.17E-05FANCI213007_at1.801.53E-06FANCI213008_at1.981.46E-06Downstrem branchBRCA2208368_s\_at1.963.45E-09BRCA2214727_at1.766.74E-08BRIP1221703_at2.041.28E-03BRIP1221703_at2.041.28E-03BRIP1221703_at2.041.28E-03BRIP1235609_at1.965.75E-05Acitvating E2FsE2F12028_s\_at1.631.89E-05E2F1204947_at2.018.72E-06E2F2235582_at1.552.28E-02E2F2228361_at1.982.97E-07E2F3203692_s\_at1.958.13E-17E2F3203693_s\_at2.211.12E-12^\*^Cutoff P-value \< 0.05.

The correlation between CNA and mRNA expression of FA/BRCA genes was determined in the basal breast tumors (n = 41; Table [4](#Tab4){ref-type="table"}). Statistical significant linear correlation (FDR P-value cut-off 5.00E-02) was found for *FANCI* and *FANCF* showing a strong linear correlation (\> 0.60), suggesting that differences in gene expression are driven by CNAs.Table 4**Significant correlation copy number variation and mRNA in basal-like tumors**Gene symbolProbe IDLinear correlation ^\*^P-valueFDR P-value^\*\*^FANCI213007_at0.773.23E-091.61E-07FANCF222713_s\_at0.734.93E-081.23E-06FANCI213008_at0.729.63E-081.61E-06E2F3203693_s\_at0.704.05E-075.06E-06FANCF218689_at0.681.19E-061.19E-05E2F3203693_s\_at0.663.04E-062.54E-05E2F3203692_s\_at0.603.75E-052.68E-04^\*^Cutoff \> 0.60; ^\*\*^Cutoff FDR P-value \< 0.05.

2.3 *E2F*involvement {#Sec7}
--------------------

To determine which E2F transcription factors could be associated with upregulation of FA genes, we studied also the mRNA expression levels of activating E2F genes (*E2F1*, *E2F2*, *E2F3*) in *RB1-*mutated retinoblastoma and in basal breast tumors.

In *RB1-*mutated retinoblastoma, all three activating E2Fs were significantly upregulated: *E2F1* (FC = 1.86, P = 2.56E-03), *E2F2* (FC = 2.84, P = 2.31E-04), and *E2F3* (FC = 3.72, P = 2.18E-10; Table [1](#Tab1){ref-type="table"}). Upregulation of the activating E2F genes was also found in basal versus not-basal breast cancer: *E2F1* (FC = 2.01, P = 8.72E-06), *E2F2* (FC = 1.98, P = 2.97E-07), and *E2F3* (FC = 1.95, P = 8.13E-17; Table [3](#Tab3){ref-type="table"}). Importantly, *E2F3* upregulation was in both cases (retinoblastoma and basal breast cancer) driven by a CNA, since a strong correlation was found between CNA and mRNA expression (FDR P-value cut-off 5.00E-02; Tables [2](#Tab2){ref-type="table"} and [4](#Tab4){ref-type="table"}).

2.4 Differential regulation of FA/BRCA genes {#Sec8}
--------------------------------------------

Established cell-cycle and E2F target genes, such as *CCNE2* are commonly robustly regulated by proliferative stimuli (see also Figure [1](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S1). To further group FA/BRCA genes in relation to cell cycle regulation and induction by proliferative stimuli we used two decision trees (Figure [2](#Fig2){ref-type="fig"}). For each criterion in the decision trees, genes received points which are summarized in Table [5](#Tab5){ref-type="table"}.Figure 2**Decision tree(s) to select coregulated genes. (a)** Decision tree for selecting FA/BRCA genes that are regulated through the cell cycle. **(b)** Decision tree to select FA/BRCA genes in RB1/E2F disturbed cells. Two cell models: retinoblastoma and breast cancer cells are screened. In both models a selection is made for "Regulated" or "Non-Regulated". In case of "Regulated" a selection is made on the possible influence of copy number alterations (CNA). Abbreviations: P = P-value; MFC = mean fold change; FC = fold change; LC = linear correlation; CNA = copy number alteration.

###### 

**Scoring scheme regulated expression FA/BRCA genes**

                                     Cell cycle model   RB1/E2F disturbed cancers           
  ------------------- -------------- ------------------ --------------------------- --- --- ---
  Core complex        FANCA          1                  1                           1   1   4
  FANCB               1              1                  0                           1   3   
  FANCC               0              1                  0                           0   1   
  FANCE               1              0                  0                           0   1   
  FANCF               0              0                  0                           0   0   
  FANCG               1              1                  1                           0   3   
  FANCL               0              1                  1                           0   2   
  FANCM               1              1                  0                           0   2   
  Central players     FANCD2         1                  1                           0   0   2
  FANCI               1              1                  1                           0   3   
  Downstream branch   FANCD1/BRCA2   1                  1                           1   0   3
  FANCN/PALB2         1              1                  1                           0   3   
  BRCA1               1              1                  1                           0   3   
                      FANCJ/BRIP1    1                  1                           1   0   3

1 point = regulated; 0 = not regulated.

In the first approach, cell cycle regulated genes were selected based on their behaviour in the human cell models. In the T98G model the average value of time point 12--16 should have a MFC \> 2.0, while in the diploid fibroblasts time point 18 should have a MFC \> 2.0 (Figure [2](#Fig2){ref-type="fig"}a). This approach allows to interrogate induction prior to entry of S phase; the usual pattern for regulation at the mRNA level for genes playing a role in S phase. Based on these criteria, "regulated" genes turned out to be the core complex members: *FANCA*, *FANCB*, *FANCG*, and *FANCM*; central players: *FANCD2* and *FANCI*; and for the downstream branch: *FANCD1/BRCA2*, *FANCN/PALB2*, *FANCJ/BRIP1*, and *BRCA1* (Additional file [2](#MOESM2){ref-type="media"}: Table S2). The core complex member *FANCE* was only considered regulated in the T98G cell line, whereas *FANCC* and *FANCL* only in the EVA-F fibroblasts. The core complex member *FANCF* was in both cell types considered not regulated.

In the second approach, to select for proliferation stimulated genes, we used the criterion 'fold change \> 2' in combination with significant P-values (Figure [2](#Fig2){ref-type="fig"}b) based on their behaviour in RB1-linked cancers. Upregulation of FA genes was found in both the retinoblastoma as well as in basal breast tumors. Only a few expression differences were possibly driven by CNA (*FANCE*, *FANCF*, and *FANCI*). The only gene that was consistently upregulated in both retinoblastoma as well as in basal breast tumors was *FANCA* (Additional file [2](#MOESM2){ref-type="media"}: Table S3).

The results of the combined scoring (Figure [2](#Fig2){ref-type="fig"}) are summarized in Table [5](#Tab5){ref-type="table"}; a gene can have maximal 4 points, reflecting induction in all 4 contexts. Only *FANCA* turned out to have 4 points. The following genes obtained all 3 points: *FANCB*, *FANCG*, *FANCI*, *FANCD1/BRCA2*, *FANCN/PALB2*, *BRCA1*, and *FANCJ/BRIP1. FANCF* turned out not to be upregulated in both cell models and in the primary tumors its expression was also low which was correlated with CNA. The results indicate differential regulation of FA genes in response to proliferative stimuli, with *FANCA* the most regulated.

### 2.4.1 *In silico*analysis to determine coregulation of FA/BRCA genes {#Sec9}

To further study coregulation, we performed *in silico* studies using the most regulated gene, i.e. *FANCA*, as the starting point. Firstly, we analyzed the correlation of *FANCA* with other genes with help of two online annotation tools, BioGPS (Wu et al. [@CR83]) and GeneFriends (<http://genefriends.org/microArray/>) (van Dam et al. [@CR75]). With the first tool BioGPS the dataset GeneAtlas U133A, gcrma was analyzed (Su et al. [@CR70]). This allowed us to interrogate the overall gene expression profile of a panel of 79 different human tissues, including several cell lines from the NCI-60 cancer cell panel. The analysis of the gene expression pattern of *FANCA* indicated a strong correlation (\> 0.7) with *BRCA1* (0.7851), and *FANCE* (0.7402; Table [6](#Tab6){ref-type="table"}).Table 6**Gene correlation mRNA expression pattern with** ***FANCA***SymbolReporterCorrelation^\*^**FANCA203806_S\_AT1.0000**CCDC85AGNF1H07976_AT0.9214SUSD3GNF1H08030_AT0.8978NLRP11GNF1H07113_AT0.8752RPAIN216962_AT0.8719WDR43214662_AT0.8525PNPT1GNF1H09065_S\_AT0.8510AICDA219841_AT0.8462C3orf37201678_S\_AT0.8370PRAMEF24PGNF1H08246_AT0.8104E2F5221586_S\_AT0.8014BACH2221234_S\_AT0.7903RFC1208021_S\_AT0.7869MRPL48GNF1H02267_S\_AT0.7864217464_AT0.7853**BRCA1204531_S\_AT0.7851**BFSP2207399_AT0.7657RMI2GNF1H08947_AT0.7636TCF3209152_S\_AT0.7603LRMP204674_AT0.7549GCSAMGNF1H07830_AT0.7536GNF1H03417_S\_AT0.7525ELL3219518_S\_AT0.7523SHMT2214095_AT0.7442**FANCE220255_AT0.7402**ZNF804A215767_AT0.7352ALDH5A1203608_AT0.7301ZNF232219123_AT0.7244LRMP35974_AT0.7173MTHFD1LGNF1H02482_S\_AT0.7126ISG15205483_S\_AT0.7115PRDM15GNF1H10126_AT0.7032^\*^Correlation Cutoff: \> 0.7; Bold: Genes of interest.

The second tool GeneFriends identifies co-expressed genes in a genome wide co-expression map over 4,000 human microarray datasets. The underlying datasets were derived from a variety of conditions. Searching GeneFriends with *FANCA* returns in the top list *FANCA* itself with a co-expressed value of 1.0 as expected. Intriguingly, only co-expression of *FANCA* with *BRCA1* was found and not with other FA/BRCA genes in the top 50 list. The co-expression value of *FANCA* with *BRCA1* was 0.708 indicating that *FANCA* is increased in expression (≥2 fold) in 70.8% of the cases when *BRCA1* is increased in expression (≥2 fold; Additional file [2](#MOESM2){ref-type="media"}: Table S4). The strong correlation of *FANCA* with *BRCA1* found with two different approaches, suggest that these two genes are frequently co-expressed. With GeneFriends, we further analyzed which genes are frequently coregulated with both *FANCA* and *BRCA1* (Additional file [2](#MOESM2){ref-type="media"}: Table S5). Enrichment analysis of this gene set revealed Medical Subject Heading Terms (MeSH; top 3; Additional file [2](#MOESM2){ref-type="media"}: Table S6) genomic instability (P-value: 4.42E-04), microcephaly (P-value: 8.33E-04), and Bloom syndrome (P-value: 3.33E-03) and an enrichment for the cellular component centrosome (GO:0005813; P-value: 3.55E-08; Additional file [2](#MOESM2){ref-type="media"}: Table S7).

### 2.4.2 Coregulation of *FANCA*and *BRCA1* {#Sec10}

Combining the results of the studies in the cell models and the tumors with the *in silico* data (Figure [2](#Fig2){ref-type="fig"}; Table [5](#Tab5){ref-type="table"}; and Additional file [2](#MOESM2){ref-type="media"}: Table S4), reveals a high degree of coregulation of *FANCA* and *BRCA1*, with *E2F3* as a possible important driver for cell-cycle regulated expression. To evaluate the degree of *FANCA*-*BRCA1* co-expression, we measured the correlation coefficient of *FANCA* and *BRCA1* expression in the Rb-tumor cohort (Figure [3](#Fig3){ref-type="fig"}). A strong linear correlation was found for co-expression of *FANCA* and *BRCA1* (Pearson: 0.72). Interestingly, when adding the *E2F3* expression to the *FANCA* and *BRCA1* gene expression correlation, tumor samples with relatively low expression of *FANCA* and *BRCA1* had also low *E2F3* and vice versa (Figure [3](#Fig3){ref-type="fig"}). This suggests a possible role for *E2F3* as a key driver for the gene regulation of the studied genes, and in particularly *FANCA* and *BRCA1*. Three established E2F3 target genes, *CCNE1*, *FEN1*, and *PCNA*, displayed a similar pattern (results not shown). As noted above, the Rb samples with *MYCN* amplifications have relative low level of expression for both genes.Figure 3**FANCA and BRCA1 are coexpressed in Retinoblastoma tumors.** Correlation of normalized intensities of the most significant probe sets of *FANCA* (x-axis: 203806_PM_s\_at, P = 2.32E-06) and *BRCA1* (y-axis: 204531_PM_s\_at, P = 2.13E-04) demonstrates a strong correlation (Pearson = 0.72). Retinoblastoma with no *RB1* mutations but with high *MYCN* amplification (orange/red dots) have relatively low expression of *FANCA* and *BRCA1*. Dot sizes indicate levels of *E2F3* expression. Retinoblastoma linked to *RB1*; blue dots: *RB1* mutation determined in tumor; grey dots: *RB1* mutation not determined in tumor. FR = Fetal Retina.

3 Discussion and conclusion {#Sec11}
===========================

We found evidence for highly divergent cell cycle regulation of FA pathway genes, with *FANCA* being the only gene upregulated ≥ 2-fold in all four assayed conditions. Cell cycle upregulation is associated with the E2F/RB1 network; inactivation of RB1 due to mutation results in higher levels of specific FA genes. Importantly, our studies also indicate that *RB1*-mutated retinoblastoma are not characterized by a general upregulation of the canonical FA pathway, since the important core complex member *FANCF* turned out to be lower expressed associated with low DNA copy numbers; a finding with direct therapeutic implications. Surprisingly, two tools exploiting public data sets indicated coregulation of *FANCA* (acting in the upstream branch of the FA network) with *BRCA1* (acting downstream).

The encoded proteins of coregulated genes often participate in the same pathway. When we characterized the expression of genes of the FA/BRCA-pathway, we found evidence for highly divergent cell type and stimulus-dependent regulation of mRNA levels for the FA pathway, which only can become apparent by in parallel comparisons as done in this study. Especially, the genes encoding for proteins which build up the core complex show strikingly different levels of cell cycle regulation. When comparing the individual subcomplexes from the core complex, one member of a subcomplex turned out to be stronger cell cycle regulated than the other member(s), e.g. FANCA versus FANCG (Figure [1](#Fig1){ref-type="fig"}b). Interestingly, the more strongly cell cycle regulated gene of each subcomplex contains Nuclear Localization Signal (NLS)-encoding sequences, while the other partner(s) lacks a positive motif score (Haitjema et al. [@CR24]). It could be hypothesized that the FA genes/proteins of the core complex bearing NLSs constitute the driving forces for nuclear complex assembly. Overall, in our assays, *FANCA* turned out to be most affected by proliferative stimuli. In line with this, *FANCA* induction had also been observed employing two other cell-cycle approaches (Whitfield et al. [@CR80]; Hoskins et al. [@CR29]). Together, this provides evidence for strong cell cycle regulation of especially *FANCA*.

As could be expected, there is an involvement of the RB1/E2F pathway in the regulation of FA genes, as had already been noted for selected FA genes (Tategu et al. [@CR72]; Hoskins et al. [@CR29]). Here, we focused on the FA/BRCA gene expression in cancers with disrupted RB1/E2F pathway, which further underscored the interplay of both pathways. Moreover, we showed that in *MYCN*-amplified retinoblastoma, with an intact RB1/E2F pathway, *FANCA* (and also *BRCA1*) are downregulated compared to *RB1*-mutated retinoblastoma. *FANCA* was also found to be upregulated in basal breast tumors compared to not-basal breast tumors.

We as well show that activating E2F genes are associated with upregulation of FA genes. Intriguingly, overexpression of *E2F3* strongly correlates with a high expression of *FANCA* and *BRCA1* in *RB1-*mutated retinoblastoma, while in *MYCN*-amplified retinoblastoma all three genes show relatively low expression. *FANCA* and *BRCA1* had already been denoted as E2F3-target genes in two other settings, while importantly no other FA/BRCA genes were identified (Polager et al. [@CR55]; Bild et al. [@CR5]). However, also other E2F genes likely contribute to the activation of FA genes (Tategu et al. [@CR72]; Hoskins et al. [@CR29]).

In all, no evidence was found for coordinate upregulation of the canonical FA pathway in response to proliferative stimuli. Due to low levels of the *FANCF* gene, the FA/BRCA-pathway may in fact be hypo-activated in full-blown retinoblastoma. Downregulation of *FANCF* mRNA levels in primary *RB1*-mutated retinoblastoma had been noted before (Ganguly and Shields [@CR22]). Hyperactivation of the FA/BRCA-pathway has been associated with resistance against certain drugs including melphalan, while repression of the FA/BRCA-pathway has been linked with sensitivity. The combination of upregulation of specific FA genes with low *FANCF* expression and therefore likely low FANCF protein might explain the intermediate melphalan sensitivity observed in retinoblastoma cell lines \[unpublished data\], and why melphalan treatment can be successful in a subset of retinoblastoma patients (Venturi et al. [@CR77]). Low levels of *FANCF* gene expression correlated with low levels of DNA was also found in basal breast cancer. Downregulation of *FANCF* due to hypermethylation of the *FANCF* promoter has also been reported in other tumors (Tischkowitz et al. [@CR74]; Narayan et al. [@CR53]; Wreesmann et al. [@CR82]). The inactivation and/or low levels of FANCF which therefore disrupts the canonical FA pathway might also enhance alternative routes/functions of FA proteins, such as e.g. a FANCA-BRCA1 subcomplex (Folias et al. [@CR21]).

In retinoblastoma upregulation of FA genes is an early event, since the first and second hit evolves mutations in the *RB1* gene. In addition, gain in copy numbers of E2F3 have already been found in retinoma, which is currently regarded as the precursor of retinoblastoma (Sampieri et al. [@CR60]). It could be hypothesized, that in early stages FA pathway activation may aid tumorigenesis. The low FANCF levels observed in full-blown tumors, nevertheless, suggest that at later stages there may be a selection against hyperactivation of the FA pathway. This order is in accordance with a recent model described for the action of the transforming human papillomavirus (HPV) E7 protein. The FA pathway has been shown to be upregulated upon HPV infection (the transforming HPV protein E7 binds to RB1 releasing E2F to transactivate its targets), though the same activated FA pathway limits the accumulation of E7 - and thereby infection or transformation - via an unknown mechanism (Hoskins et al. [@CR30]). Therefore, both in viral and non-viral *RB1*-linked cancers, an early general upregulation of the FA network may be followed by a dampening of the same network via other mechanisms (Figure [4](#Fig4){ref-type="fig"}). Upregulation of FA genes could be related to prevention of replication stress in which the FA/BRCA pathway plays a role (Schlacher et al. [@CR61]). Reduction of replication stress at certain times of tumorigenesis might reduce DNA-damage induced apoptosis thereby facilitating tumorigenesis (Hills and Diffley [@CR28]).Figure 4**Retinoblastoma and FA/BRCA pathway transformation model.** First and second hits in retinoblastoma are the inactivation of the RB1 alleles. Gain of E2F3 copy numbers aids to the upregulation of specific FA genes. In later stage inactivation of the FA/BRCA-pathway may be accomplished via low levels of the FANCF DNA/RNA, resulting in melphalan sensitivity.

Our analysis suggests also the possible relevance of subnetworks of the FA pathway in pathology. Two tools exploiting public data sets indicated coregulation of *FANCA* - functioning in the upstream branch of the classic FA network - with *BRCA1* functioning in the downstream branch. In fact, coregulation of *FANCA* and *BRCA1* was also observed in studies on the transcription factor SMAD4 (Bornstein et al. [@CR7]; Meier and Schindler [@CR52]). In our previous published prioritization approach based on FA protein properties, BRCA1 and FANCA were number one and three, respectively (Haitjema et al. [@CR24]); resembling also each other on multiple intrinsic protein properties.

Additional analysis of genes co-expressed with *FANCA* and *BRCA1*, showed enrichment for the cellular component centrosome. In line with this, FANCA and BRCA1, but also the inducing transcription factor E2F3, have all three been associated with centrosome function (Saavedra et al. [@CR59]; Kais et al. [@CR34]; Kim et al. [@CR37]); loss gives rise to aberrant centrosomes. Importantly, in BRCA1 this function could be separated from its function in homologous recombination. In accordance with this, in uterine leiomyomas *FANCA* and *BRCA1* are both lowly expressed (Cirilo et al. [@CR10]), and these tumors display centrosome dysfunction (Shan et al. [@CR62]). Intriguingly, centrosome amplification causes microcephaly (Marthiens et al. [@CR47]), a MeSH term we find enriched in the co-expressed genes.

BRCA1 has not been considered an FA gene, until recently, when a female patient diagnosed with ovarian cancer appeared to harbour biallelic mutations in *BRCA1* and should be regarded as a FA patient (Domchek et al. [@CR18]). The affected individual presented with microcephaly and, as expected, was extremely sensitive to cross-linking drugs. Since BRCA1 and FANCA have been shown to interact (Folias et al. [@CR21]), this warrants further study to explore how precisely FANCA and BRCA1 interact.

In summary, FA genes show a variable level of cell cycle regulation. Upregulation of a subset of genes of the FA network may be a common theme in *RB1*-mutated tumors. There may be a selection, however, against hyperactivation of the classic FA pathway in certain tumors. Furthermore, this study warrants further molecular studies of subcomplexes containing specific FA proteins, besides the canonical FA pathway, and their relevance for pathology, carcinogenesis and therapy response.

4 Methods {#Sec12}
=========

4.1 Cell and culture conditions {#Sec13}
-------------------------------

T98G glioblastoma cells (obtained from ATCC®) were cultured in Dulbecco's modified Eagle medium (DMEM) containing 1 g/L D-Glucose supplemented with 10% foetal bovine serum (FBS). EVA-F primary diploid fibroblasts (obtained from a 23-year old female control; established and propagated at VUmc) were cultured in DMEM containing 4.5 g/L D-Glucose supplemented with 10% foetal bovine serum (FBS). To induce growth arrest, subconfluent cells were grown for 72 h in DMEM supplemented with 0.2% FBS. Cells were harvested at specific time points after restimulation with 10% FBS. Cell cycle analysis was performed as described previously (Stoepker et al. [@CR68]). For EVA-F fibroblast, the karyotype was determined (EVA-F: 45.18 ± SEM 0.25 chromosomes, n = 40 metaphases).

4.2 RT-PCR and quantitative real-time PCR {#Sec14}
-----------------------------------------

Total RNA was extracted (High Pure Isolation Kit; Roche) and cDNA was prepared (iScriptcDNA Synthesis Kit; Biorad). The mRNA levels were quantified by real-time quantitative polymerase chain reactions (SYBR Green reaction kit; LightCycler 480, Roche). Relative gene expression, in terms of mean fold changes (MFC), was calculated via the 2^-ΔΔC^~T~ method (Livak and Schmittgen [@CR45]). Primer design was optimized for quantitative mRNA profiling. The primers generated amplicons of \~100 to 250 bp with a minimum GC content of 40%; forward and reverse primers were on different exons to avoid genomic products (except for *FANCF* which has only on exon). As controls, primer sets for the established cell cycle marker gene *CCNE2* and for the housekeeping gene *TBP* were used. Specific primer pairs were designed using the Primer3 program (Primer3 Version 0.4.0; <http://bioinfo.ut.ee/primer3-0.4.0/primer3/>) for the genes as follows: *FANCA*: 5′-CACACGCTTGGCAGTGTAAT-3′ and 5′-CGCAAAGCTCCACTCTCTCT-3′;*FANCB*: 5′-CGCTGCGTTGAGTTTCATAA-′3 and 5′-TGGGACAATAGGCATCACAA-3′;*FANCC*: 5′-ATTCCGGGTTGTTGATGAGA-3′and 5′-TGCTTGCTTGCTTTCTCCAG-3′;*BRCA2/FANCD1*: 5′-ATGGCTCATACCCTCCAATG-3′ and 5′-TTCCATAGCTGCCAGTTTCC-3′;*FANCD2*: 5′-TCCGACTTGACCCAAACTTC-3′ and 5′-GTGATGGCAAAACACAATGC-3′;*FANCE*: 5′-TGATCTCAGCCTCAGCAATG-3′ and 5′-GGAGGTCAGGGCAGTTGTAA-3′;*FANCF*: 5′-CTAACTGCCCTGGAGACCTG-3′ and 5′-CGCTGAGACCCAAAACTTGT-3′;*FANCG*: 5′-CGCCCTAATTAGTCGTGGAC-3′ and 5′-TCCCTCCGATCTAGCCTCTT-3′;*FANCI*: 5′-AAGCGGGTAAAGCCAAAACT-3′ and 5′-CGCATAAACTCATTGCTGGA-3′;*BRIP1/FANCJ*: 5′-GCTCTCAGAAGTCGGTTTCC-3′ and 5′-AGCAAGCTGTGACGGGTAAG-3′;*FANCL*: 5′-GAAATTGATTTTCCAGCTCGTG-3′ and 5′-TGGTACCGTCAAGTTGATAAGC-3′;*FANCM*: 5′-CACGAAGGGTTTTACCCAGA-3′ and 5′-ACCTTCTTCACCCACACAGG-3′;*PALB2/FANCN*: 5′-CTTGGCCTGACAAAGAGGAG-3′ and 5′-AAGCAGAGCTTCTTGCATCC-3′;*BRCA1*: 5′-GAGTGAACCCGAAAATCCTTC-3′ and 5′-ACTGATTTCATCCCTGGTTCC-3′;*CCNE2*: 5′-ACTGACTGCTGCTGCCTTGTGC-3′ and 5′-TCGGTGGTGTCATAATGCCTCC-3′;*TBP*: 5′-TGCACAGGAGCCAAGAGTGAA-3′and 5′-CACATCACAGCTCCCCACCA-3′.

4.3 Gene expression profiling {#Sec15}
-----------------------------

### 4.3.1 Primary retinoblastoma tumors {#Sec16}

Total RNA was isolated from 77 primary retinoblastoma tumors and 3 healthy fetal retina tissues (including 2 biological duplicates adding up to 5 control RNA-extracts). Biotinylated targets were prepared by published methods (Lipshutz et al. [@CR44]) and hybridized to Affymetrix HT HG-U133 Plus PM arrays. Resulting raw CEL-files were normalized by robust multi-array average implementated by Bioconductor package affy (Gautier et al. [@CR23]). To identify genes differentially expressed between the retinoblastoma tumors and healthy fetal retina, empirical Bayes moderated t-statistics were calculated, implemented by the limma package (Smyth [@CR65]) and p-values were adjusted by Benjamini and Hochberg multiple testing correction (Benjamini and Hochberg [@CR4]).

### 4.3.2 Basal and not-basal breast tumors {#Sec17}

Total RNA was isolated from 41 basal breast tumors (27 *BRCA1* mutated) and 79 not-basal breast tumors (8 *BRCA1* mutated) and cryostat sections using RNAzol B (Campro Scientific, Veenendaal, The Netherlands) and RNA quality and quantity was evaluated on a Agilent Bioanalyzer. Antisense biotinylated RNA was prepared and hybridized to Affymetrix HGU133_Plus_2.0 GeneChips, according to the manufacturer's guidelines (Affymetrix, Santa Clara, CA, USA). Gene expression signals were calculated using AffymetrixGeneChip analysis software MAS 5.0. Global scaling normalization was performed to bring the average signal intensity of the chips to a target of 100 before data analysis. The data was imported in Partek Genomics Suite 6.5 and Log2 transformed before analysis. ANOVA was then used to determine differentially expressed probe-sets.

4.4 Analysis of public data sets and gene set enrichment analysis {#Sec18}
-----------------------------------------------------------------

Two online annotation tools were used for in silico coregulation analysis: BioGPS (Wu et al. [@CR83]) and GeneFriends (<http://genefriends.org/microArray/>) (van Dam et al. [@CR75]). With BioGPS the data set GeneAtlas U133A, gcrma was analyzed, with the cut-off: \>0.7 (Su et al. [@CR70]). The human co-expression network was screened in GeneFriends. Enrichment analysis was performed with Genomatix GeneRanker (Genomatix Software GmbH, version 2013).

4.5 Ethical standards {#Sec19}
---------------------

Retinoblastoma and breast cancer specimens were processed and analyzed in accordance with local ethics (VUmc).
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###### 

Additional file 1: Figure S1: Differential cell cycle regulation of FA genes in human EVA-F cells. (a - left panel) Cells were placed on medium with low serum (0.2% FBS) for 3 days resulting in cell cycle arrest. The addition of high serum medium (10% FBS) released cells resulting in synchronous progression through the cell cycle. Sampled cells at different time points were divided for Fluorescent Activated Cell Sorting (FACS) analysis. Data represents one representative synchronization experiment. Quantitative RT-PCR was performed on RNA samples from different time points and mean fold changes (MFC) were calculated relative to time point zero. Data represents duplo qPCR measurements of one representative synchronization experiment, SEM is indicated. (a - right panel) Cell cycle control *CCNE2* (b) *FANCA* and *FANCG* (c) *FANCB* and *FANCL* (d) *FANCE*, *FANCC*, and *FANCF* (e) *FANCM* (f) *FANCD2* and *FANCI* (g) *BRCA2, PALB2, BRCA1,* and *BRIP1*. (TIFF 612 KB)

###### 

Additional file 2: Table S1: Expression in retinoblastoma tumors with *MYCN* amplification versus retinoblastoma tumors with *RB1* mutations. **Table S2** Summary regulation FA/BRCA-pathway genes cell model. **Table S3** Summary results FA/BRCA-pathway genes "RB1/E2F disturbed cells". **Table S4** Co-expressed genes with input gene *FANCA*. **Table S5** Co-expressed genes with input gene *FANCA* and *BRCA1*. **Table S6** Medical Subject Headings (MeSH) enrichment of 50 genes co-expressed with *FANCA* and *BRCA1*. **Table S7** Cellular Components (GO) enrichment of 50 genes co-expressed with *FANCA* and *BRCA1*. (DOC 210 KB)
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